JP2016501843A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501843A5 JP2016501843A5 JP2015540216A JP2015540216A JP2016501843A5 JP 2016501843 A5 JP2016501843 A5 JP 2016501843A5 JP 2015540216 A JP2015540216 A JP 2015540216A JP 2015540216 A JP2015540216 A JP 2015540216A JP 2016501843 A5 JP2016501843 A5 JP 2016501843A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antibody
- lymphoma
- fragments
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101001018034 Homo sapiens Lymphocyte antigen 75 Proteins 0.000 claims 25
- 102100033486 Lymphocyte antigen 75 Human genes 0.000 claims 25
- 239000012634 fragment Substances 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 11
- 238000000034 method Methods 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 206010025323 Lymphomas Diseases 0.000 claims 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 206010005003 Bladder cancer Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 201000010536 head and neck cancer Diseases 0.000 claims 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims 3
- 201000000849 skin cancer Diseases 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 201000002510 thyroid cancer Diseases 0.000 claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims 3
- 208000003950 B-cell lymphoma Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 2
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 229930126263 Maytansine Natural products 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 claims 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 108010044540 auristatin Proteins 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims 1
- 229930195731 calicheamicin Natural products 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 claims 1
- 229960005501 duocarmycin Drugs 0.000 claims 1
- 229930184221 duocarmycin Natural products 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 210000003563 lymphoid tissue Anatomy 0.000 claims 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 1
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 1
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 230000035479 physiological effects, processes and functions Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1220010.1A GB201220010D0 (en) | 2012-11-07 | 2012-11-07 | Therapeutic amd diagnostic target |
| GB1220010.1 | 2012-11-07 | ||
| PCT/GB2013/052899 WO2014072700A1 (en) | 2012-11-07 | 2013-11-06 | Ly75 as cancer therapeutic and diagnostic target |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018141190A Division JP7079685B2 (ja) | 2012-11-07 | 2018-07-27 | 癌治療および判断ターゲットとしてのｌｙ７５ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016501843A JP2016501843A (ja) | 2016-01-21 |
| JP2016501843A5 true JP2016501843A5 (OSRAM) | 2016-11-24 |
Family
ID=47429281
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540216A Pending JP2016501843A (ja) | 2012-11-07 | 2013-11-06 | 癌治療および判断ターゲットとしてのｌｙ７５ |
| JP2018141190A Active JP7079685B2 (ja) | 2012-11-07 | 2018-07-27 | 癌治療および判断ターゲットとしてのｌｙ７５ |
| JP2020154083A Pending JP2021011483A (ja) | 2012-11-07 | 2020-09-14 | 癌治療および判断ターゲットとしてのｌｙ７５ |
| JP2022177986A Active JP7479435B2 (ja) | 2012-11-07 | 2022-11-07 | 癌治療および判断ターゲットとしてのｌｙ７５ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018141190A Active JP7079685B2 (ja) | 2012-11-07 | 2018-07-27 | 癌治療および判断ターゲットとしてのｌｙ７５ |
| JP2020154083A Pending JP2021011483A (ja) | 2012-11-07 | 2020-09-14 | 癌治療および判断ターゲットとしてのｌｙ７５ |
| JP2022177986A Active JP7479435B2 (ja) | 2012-11-07 | 2022-11-07 | 癌治療および判断ターゲットとしてのｌｙ７５ |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20150297743A1 (OSRAM) |
| EP (1) | EP2917239A1 (OSRAM) |
| JP (4) | JP2016501843A (OSRAM) |
| KR (1) | KR102256552B1 (OSRAM) |
| CN (2) | CN113181372A (OSRAM) |
| AU (2) | AU2013343277B2 (OSRAM) |
| BR (1) | BR112015009438B1 (OSRAM) |
| CL (1) | CL2015001098A1 (OSRAM) |
| EA (1) | EA033649B1 (OSRAM) |
| GB (1) | GB201220010D0 (OSRAM) |
| HK (1) | HK1214611A1 (OSRAM) |
| NZ (1) | NZ707116A (OSRAM) |
| SG (2) | SG11201503363WA (OSRAM) |
| UA (1) | UA117569C2 (OSRAM) |
| WO (1) | WO2014072700A1 (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201220010D0 (en) * | 2012-11-07 | 2012-12-19 | Oxford Biotherapeutics Ltd | Therapeutic amd diagnostic target |
| BR112016007402B1 (pt) | 2013-10-11 | 2023-03-28 | Oxford Biotherapeutics Ltd | Anticorpo isolado, ou uma porção de ligação de antígeno deste, composição farmacêutica o compreendendo e seu uso, bem como ácido nucléico, vetor de expressão e método de produção de um anticorpo ou uma porção de ligação de antígeno deste |
| EP3303625B1 (en) | 2015-05-29 | 2019-03-27 | Universiteit Maastricht | Method for identifying subjects with aggressive melanoma skin cancer at diagnosis |
| KR101796091B1 (ko) | 2016-05-02 | 2017-11-10 | 충남대학교 산학협력단 | 카복실 말단 조절 단백질을 포함하는 두경부암 진단용 바이오 마커 조성물 |
| GB201703876D0 (en) | 2017-03-10 | 2017-04-26 | Berlin-Chemie Ag | Pharmaceutical combinations |
| GB201809746D0 (en) | 2018-06-14 | 2018-08-01 | Berlin Chemie Ag | Pharmaceutical combinations |
| CN109685135B (zh) * | 2018-12-21 | 2022-03-25 | 电子科技大学 | 一种基于改进型度量学习的少样本图像分类方法 |
| WO2021108637A1 (en) * | 2019-11-26 | 2021-06-03 | Cedars-Sinai Medical Center | Compositions and methods for treating diseases and conditions by depletion of mitochondrial or genomic dna from circulation |
| EP4397673A4 (en) | 2021-08-31 | 2025-02-19 | FUJIFILM Corporation | COMPOUND AND MARKED BIOMATERIAL USING SAME |
| EP4397672A4 (en) | 2021-08-31 | 2025-02-26 | FUJIFILM Corporation | Compound and labeled biomaterial using same |
| JPWO2023032994A1 (OSRAM) | 2021-08-31 | 2023-03-09 | ||
| US20230113866A1 (en) * | 2021-09-13 | 2023-04-13 | Regeneron Pharmaceuticals, Inc. | Methods Of Treating Clonal Hematopoiesis Of Indeterminate Potential (CHIP) With Lymphocyte Antigen 75 (LY75), Cluster Of Differentiation 164 (CD164), Or Poly(ADP-Ribose) Polymerase 1 (PARP1) Inhibitors |
| EP4644874A1 (en) | 2022-12-26 | 2025-11-05 | FUJIFILM Corporation | Fluorescence intensity enhancing agent, method for enhancing fluorescence intensity of fluorescently labeled target biological material, and fluorescence detection kit |
| WO2024181455A1 (ja) | 2023-02-27 | 2024-09-06 | 富士フイルム株式会社 | 化合物及びこれを用いた標識生体物質 |
| JPWO2024181454A1 (OSRAM) | 2023-02-27 | 2024-09-06 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US20040258688A1 (en) * | 1995-01-31 | 2004-12-23 | Daniel Hawiger | Enhanced antigen delivery and modulation of the immune response therefrom |
| WO1997045449A1 (en) * | 1996-05-29 | 1997-12-04 | Derek Nigel John Hart | Dendritic cell receptor |
| IL157145A0 (en) * | 2001-01-31 | 2004-02-08 | Idec Pharma Corp | Use of dc23 antagonists for the treatment of neoplastic disorders |
| US20040146948A1 (en) * | 2002-10-18 | 2004-07-29 | Centenary Institute Of Cancer Medicine And Cell Biology | Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments |
| WO2008104803A2 (en) * | 2007-02-26 | 2008-09-04 | Oxford Genome Sciences (Uk) Limited | Proteins |
| WO2008154333A2 (en) * | 2007-06-08 | 2008-12-18 | Asuragen, Inc. | Mir-34 regulated genes and pathways as targets for therapeutic intervention |
| SG187482A1 (en) * | 2007-11-07 | 2013-02-28 | Celldex Therapeutics Inc | Antibodies that bind human dendritic and epithelial cell 205 (dec-205) |
| EP2159291A1 (en) * | 2008-09-01 | 2010-03-03 | Agendia B.V. | Means and method for determining tumor cell percentage in a sample |
| AU2010303304A1 (en) * | 2009-10-08 | 2012-05-17 | President And Fellows Of Harvard College | Methods and compositions for amelioration of autoimmune disease using fusion proteins of anti-dendritic cell receptor antibody to peptide sequences |
| TW201247706A (en) * | 2011-03-08 | 2012-12-01 | Baylor Res Inst | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
| GB201220010D0 (en) * | 2012-11-07 | 2012-12-19 | Oxford Biotherapeutics Ltd | Therapeutic amd diagnostic target |
| JP6431104B2 (ja) * | 2017-02-27 | 2018-11-28 | オリコン株式会社 | マイクロ波を利用した金属蒸気の発生方法 |
-
2012
- 2012-11-07 GB GBGB1220010.1A patent/GB201220010D0/en not_active Ceased
-
2013
- 2013-06-11 UA UAA201504407A patent/UA117569C2/uk unknown
- 2013-11-06 KR KR1020157011701A patent/KR102256552B1/ko active Active
- 2013-11-06 SG SG11201503363WA patent/SG11201503363WA/en unknown
- 2013-11-06 NZ NZ707116A patent/NZ707116A/en unknown
- 2013-11-06 BR BR112015009438-4A patent/BR112015009438B1/pt active IP Right Grant
- 2013-11-06 EA EA201590694A patent/EA033649B1/ru unknown
- 2013-11-06 SG SG10201810357WA patent/SG10201810357WA/en unknown
- 2013-11-06 AU AU2013343277A patent/AU2013343277B2/en active Active
- 2013-11-06 US US14/440,483 patent/US20150297743A1/en not_active Abandoned
- 2013-11-06 CN CN202110466746.1A patent/CN113181372A/zh active Pending
- 2013-11-06 JP JP2015540216A patent/JP2016501843A/ja active Pending
- 2013-11-06 CN CN201380056271.2A patent/CN104755496A/zh active Pending
- 2013-11-06 EP EP13789381.4A patent/EP2917239A1/en active Pending
- 2013-11-06 WO PCT/GB2013/052899 patent/WO2014072700A1/en not_active Ceased
- 2013-11-06 HK HK16102576.0A patent/HK1214611A1/zh unknown
-
2015
- 2015-04-27 CL CL2015001098A patent/CL2015001098A1/es unknown
-
2018
- 2018-05-17 AU AU2018203478A patent/AU2018203478B2/en active Active
- 2018-07-27 JP JP2018141190A patent/JP7079685B2/ja active Active
-
2019
- 2019-04-24 US US16/392,796 patent/US20190317100A1/en not_active Abandoned
-
2020
- 2020-09-14 JP JP2020154083A patent/JP2021011483A/ja active Pending
- 2020-11-18 US US16/951,023 patent/US20210346512A1/en not_active Abandoned
-
2022
- 2022-11-07 JP JP2022177986A patent/JP7479435B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016501843A5 (OSRAM) | ||
| NZ707116A (en) | Ly75 as cancer therapeutic and diagnostic target | |
| JP2016513094A5 (OSRAM) | ||
| CY1124723T1 (el) | Μορια προσδεσης pd-1 και μεθοδοι χρησης αυτων | |
| FI3332006T3 (fi) | Uusia anti-PD-L1-vasta-aineita | |
| JP2010518847A5 (OSRAM) | ||
| IL272572A (en) | Antibody compositions for tumor treatment | |
| JP2011509079A5 (OSRAM) | ||
| UA90082C2 (ru) | Выделенное моноклональное антитело человека, которое специфически связывается с cd25 человека и ингибирует связывание il-2 с cd25 | |
| JP2017501137A5 (OSRAM) | ||
| RU2014133069A (ru) | Транслокации r-спондина и способы с их использованием | |
| EP2210939A4 (en) | Anti-bst2 antibody | |
| JP2014513068A5 (OSRAM) | ||
| JP2013506675A5 (OSRAM) | ||
| JP2009536834A5 (OSRAM) | ||
| RU2018125490A (ru) | Нейтрализация ингибиторных путей в лимфоцитах | |
| JP2013507968A5 (OSRAM) | ||
| RU2014140119A (ru) | Способы повышения эффективности терапии на основе cd37 | |
| JP2015514716A5 (OSRAM) | ||
| US20150361504A1 (en) | Biomarker for predicting response of cll to treatment with a btk inhibitor | |
| JP2016502091A5 (OSRAM) | ||
| Afonso et al. | QCM immunoassay for recombinant cysteine peptidase: A potential protein biomarker for diagnosis of citrus canker | |
| JP2010535506A5 (OSRAM) | ||
| JP2015523852A5 (OSRAM) | ||
| JP2014223083A5 (OSRAM) |